Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced that new data from the companys chronic hepatitis C
virus (HCV) clinical development programs will be presented at The
Liver Meeting 2016. Fifteen scientific abstracts,
including seven oral and eight poster presentations, will highlight
findings from Mercks HCV clinical development programs.
Language:
English
Contact:
MerckMedia:Doris Li, 908-740-1903Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more